Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ chronic myeloid leukemia patients treated with imatinib mesylate

Journal of Experimental and Clinical Cancer Research

Volumn 23, Issue 2, 2004, Pages 295-299

  Fugazza, G ^a   Miglino, M ^a   Bruzzone, R ^a   Quintino, S ^a   Gatti, A M ^a   Grasso, R ^a   Gobbi, M ^a   Frassoni, F ^a   Sessarego, Mario ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Chromosome Philadelphia; Chronic myeloid leukemia; Fluorescent in situ hybridization; Imatinib therapy

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CHROMOSOME BANDING PATTERN; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; INTERPHASE; INTERPHASE CHROMOSOME; METAPHASE CHROMOSOME; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW; CHROMOSOME BANDING; CYTOGENETIC ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERFERON-ALPHA; INTERPHASE; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; METAPHASE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SALVAGE THERAPY; SURVIVAL RATE;

EID: 3242723218     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Eng. J. Med. 330:820-825, 1994.
2. Kantarjian H.M., O'Brien S., Smith T.L., Rios M.B., Cortes J., Beran M., et al.: Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukaemia with daily doses of interferon alpha and low-dose cytarabine. J. Clin. Oncol. 17:284-292, 1999.
3. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:561-566, 1996.
4. Deininger M.W., Goldman J.M., Lydon N., Melo J.V.: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691-3698, 1997.
5. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N. Eng. J. Med. 344:1031-1037, 2001.
6. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukaemia with the Philadelphia chromosome. N. Eng. J. Med. 344:1038-1042, 2001.
7. Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., Ottmann O.G., et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukaemia in myeloid blast crises: results of a phase II study. Blood 99:3530-3539, 2002.
8. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myeloid leukemia. N. Eng. J. Med. 346:645-652, 2002.
9. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al.: Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. N. Eng. J. Med. 348:994-1004, 2003.
10. Bhatia R., Holtz M., Niu N., Gray R., Snyder D.S., Sawyers C.L., et al.: Persistence of malignant hematopoietic progenitors in chronic myelogenous leukaemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101:4701-4707, 2003.
11. Kaeda J., Chase A., Goldman J.M.: Cytogenetic and Molecular Monitoring of Residual Disease in Chronic Myeloid Leukaemia. Acta Haematol. 107:64-75, 2002.
12. Kantarjian H.M., Talpaz M., Cortes J., O'Brien S., Faderl S., Thomas D., et al.: Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia. Clin. Cancer. Res. 9:160-166, 2003.
13. Gambacorti-Passerini C., le Coutre P., Mologni L., Fanelli M., Bertazzoli C., Marchesi E., et al.: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 23:380-394, 1997.